



ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

CNPJ/ME 12.104.241/0004-02

NIRE 35.300.493.699

Publicly Traded Company

MATERIAL FACT

Oncoclínicas do Brasil Serviços Médicos S.A. (B3: ONCO3) ("Company"), in compliance with paragraph 4th, article 157 of Law 6,404/76, as amended ("Brazilian Corporation Law"), CVM Resolution Number 44/21 and CVM Resolution Number 77/22, hereby informs its shareholders and the market that its Board of Directors approved today the launching of a share buyback program ("Buyback Program").

Purpose: to maximize value for the Company's shareholders through an efficient capital allocation, by means of the acquisition of the Company's common shares, which could be held in treasury, sold in the market in the future, cancelled, or used in the Company's long-term incentives plans.

Number of shares to be acquired: up to 14,000,000 (fourteen million) common shares issued by the Company, corresponding to up to 8.8% of the common shares issued by the Company at the present date, as defined in article 1, sole paragraph, item I of CVM Resolution No. 77/22; subject to the limit provided for in article 9 of CVM Resolution 77/22 and the minimum percentage of outstanding shares of 25% (twenty-five percent), as defined in the Listing Regulation of the Brazilian market (*Novo Mercado*).

Term: the Buyback Program approved herein may be carried out at the Company's convenience, through its management, in compliance with article 7 of CVM Resolution No. 77/22, within a period of up to 18 (eighteen) months from the present date.

Resources for the Buyback Program: the transactions carried out under the Buyback Program will be supported by the global amount of the Company's capital reserves. The Company has a capital reserve in an amount sufficient for the execution of the Share Buyback Program.

Price and method of acquisition: the purchases will be carried out at B3 - Brasil, Bolsa, Balcão ("B3"), at market prices, and the Company's management will decide the moment and the number of shares to be acquired, whether in a single transaction or in a series of transactions, subject to the limits set forth in the applicable regulations.

Financial Institutions: the purchase of the Company's shares will be executed by Citigroup Global Markets Brasil Corretora de Câmbio, Títulos e Valores Mobiliários S.A., enrolled with the CNPJ/ME under No33.709.114/0001-64.



Additional Information: the Company will keep its shareholders and the market informed about the progress of the Buyback Program through the disclosure of a Notice to the Market or Material Fact at the CVM (www.cvm.gov.br), B3 (www.b3.com.br) and the Company's (<https://ri.grupooncoclinicas.com/>) websites.

São Paulo, July 6th, 2022.

Cristiano Camargo

Investor Relations Officer

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.